Henry Ford Hospital Medical Journal
Volume 36

Number 1

Article 15

3-1988

Enteric-Coated Fenoprofen in Large-Joint Osteoarthritis
Gilbert B. Bluhm
Harris H. MacIlwain
Walter W. Offen

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Bluhm, Gilbert B.; MacIlwain, Harris H.; and Offen, Walter W. (1988) "Enteric-Coated Fenoprofen in LargeJoint Osteoarthritis," Henry Ford Hospital Medical Journal : Vol. 36 : No. 1 , 56-60.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol36/iss1/15

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.

Enteric-Coated Fenoprofen in Large-Joint Osteoarthritis*
Gilbert B. Bluhm, MD,* Harris H. Macllwain, MD,* and Walter W. Offen, PhD§

Enteric-coatedfenoprofen was compared with standardfenoprofen (Nalfon"", Dista, Indianapolis, IN)
'in a randomized, double-blind, parallel, three-month trial of 113 outpatients (mean age, 64 years)
wilh large-joint osteoarthritis. A previous study showed that enteric coating offenoprofen reduces
gastrointestinal microbleeding and may offer a safety advantage. Both treatments provided
slalistically significant improvement in pain measures (tenderness on pressure, pain at rest, pain with
weight-bearing activity, and pain on passive motion). Adverse experiences were simitar wilh both
treatments and ofan expected type, severity, and incidence for nonsteroidal anti-inflammatory drugs.
Enteric-coated fenoprofen was found to be as effective and safe as standardfenoprofen for large-joint
osteoarthritis. (Henry Ford Hosp MedJ 1988:36:56-60)

enoprofen calcium (Nalfon®. Dista, Indianapolis, IN) is a
nonsteroidal anti-inflammatory dmg (NSAID) with analgesic and antipyretic properties. Although its exact mode of
action is not known, inhibition of prostaglandin synthetase is
probably involved. As an NSAID, fenoprofen has proven to be
effective in the treatment of rheumatoid arthritis and large-joint
osteoarthritis (1). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by a reduction in the common measures of disease
activity. Efficacy and safety of fenoprofen compare favorably
with those of other agents used to treat osteoarthritis, such as
aspirin (2-4), indomethacin (5), ibuprofen (6), and sulindac (7).
However, fenoprofen, like other NSAIDs, is known to produce
gastrointestinal (GI) irritation, bleeding, and other GI symptoms (8). While studies have shown that fenoprofen is safer than
aspirin and no long-term clinical risks are associated with its use
for treatment of osteoarthritis (8-10), it is important to minimize
risks of GI bleeding.
To protect the mucosal membrane of the stomach from irritation produced by aspirin and NSAIDs, enteric coatings have
been developed that do not change the biologic half-life of the
drug (11). A recent study showed that an enteric-coated form of
fenoprofen reduced GI microbleeding significantly (12). The
bioavailability of the two formulations is equal (data on file,
Lilly Research Laboratories, Indianapolis, IN).
The purpose of this study was to compare the two formulations to determine whether the enteric-coated form is as
effective and safe as standard fenoprofen calcium. If so, enteric-coated fenoprofen may have fewer adverse Gl effects than
fenoprofen calcium when used for the long-term treatment of
large-joint osteoarthritis.

F

Materials and Methods
Patient population
Male and female ambulatory outpatients, 18 years or older,
with active osteoarthritis were selected forthe study. All patients
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were taking fenoprofen calcium for their disease condition
immediately before the trial began. Six independent clinical
centers participated in the study.
The presence of osteoarthritis was established by the following diagnostic criteria: roentgenological evidence of large-joint
(hip or knee) osteoarthritis and one or more of the following
signs and symptoms of osteoarthritis: tenderness on pressure,
pain on passive motion, pain with weight-bearing activity,
or pain at rest. The symptomatic knee or hip was the cardinal
joint evaluated.
Patients were excluded from the study if they had:
• evidence of rheumatoid arthritis, lupus erythematosus,
psoriasis, syphilitic neuropathy, or metabolic bone disease;
• cardiac, renal, hepatic, gastrointestinal, or other serious diseases that would be exacerbated by the study medications or interfere with study evaluation;
• hypersensitivity to fenoprofen calcium, aspirin, orother
drugs;
• history of alcohol or drug abu.se within one year;
• clinically significant psychiatric problems;
• inability to take oral medications.
Patients with serious di.seases were accepted into the study
only if the investigator determined that the condition(s) would
not interfere with the study evaluation. Women of childbearing
age were included if they were on an effective contraceptive program approved by the investigator. The study protocol was
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approved by the institutional review boards at each of the
participating centers, and all patients signed an informed consent form.
Study design
The study was a randomized, double-blind, parallel ttial conducted at six centers by independent investigators. The study began with a two-week placebo qualification period during which
patients were withdrawn from fenoprofen calcium to demonstrate active osteoarthritis symptoms and to eliminate apparent
placebo reactors by indicating the need for active medication.
During this time, patients were allowed to take acetaminophen
(500 mg) if they required an analgesic to relieve pain. Ifthe
symptoms of osteoarthritis became unbearable, the placebo period was shortened and the patient entered the active treatment
phase before the two-week period ended.
After this two-week period, eligible patients were randomly
allocated to one of two treatment groups: fenoprofen calcium,
600 mg, or enteric-coated fenoprofen, 600 mg. Patients who entered the active treatment phase received one of the two medications four times a day for 12 consecutive weeks. No adjustments
in dosage were permitted, and patients were not allowed to
switch formulations. Compliance was assessed at each visit by
counting capsules and by measuring serum fenoprofen calcium
concentrations. Additional analgesics were not permitted during
the active treatment period.
Patients were evaluated by the investigator at four regulariy
scheduled visits during the three-month period. At each visit,
the investigator evaluated clinical symptoms of osteoarthritis,
recorded any adverse events, dispensed the study medication,
and collected blood or urine samples. At the conclusion of the
final visit, the investigator prepared a final summary report for
each patient.
Measures of efficacy
Four pain parameters were used to measure the patient's response to the study medication: tenderness on pressure and pain
on passive motion, which were evaluated directiy by the clinician, and pain at rest and pain with weight-bearing activity,
which were evaluated through interview of the patient. At each
visit, the investigator rated these parameters on a four-point
scale: 0 = no pain, I = mild pain, 2 = moderate pain, and 3 =
severe pain. To minimize variation, the same investigator evaluated the same patient at each visit at approximately the same
time of day.
Statistical analysis
The four efficacy variables were analyzed in two ways. First,
changes from baseline to endpoint were analyzed by analysis of
variance (ANOVA) on the ranks of the data. ANOVA was performed twice, first on all data and then on evaluable data alone.
Baseline was the visit at which the treatment phase began, and
endpoint was the last visit for which data were collected.
ANOVA included three independent variables: investigator,
drugs, and their interaction. In addition, a Wilcoxon rank sum
test, which does not account for any differences due to investigators, was performed on the four efficacy variables, and a
Wilcoxon signed rank test was used to analyze the two treatment
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groups individually for any significant changes within the
group. The second form of analysis used the same statistical
techniques as the first, but in this case changes from baseline to
each of the three months of the study were analyzed separately.
A standard Pearson chi-square test was used to analyze three
primary reasons for termination from the study: protocol completed, lack of efficacy, or adverse events. For this study, statistical significance was defined as P ^ 0.05. All treatment
comparisons were two-tailed.
Laboratory studies
Samples were collected at the beginning of the placebo qualification period and at the end of the last visit for blood chemistry
profiles, hematological tests, and urinalysis. Compliance blood
samples were drawn after each ofthe three months of treatment.
Adverse events
An adverse event was defined as any undesired occurrence
during treatment with the medication whether or not it was considered drug-related. These included any deaths or hospitalizations, withdrawal from the study due to a serious adverse event,
change in renal function or proteinuria, melena or Gl perforation, obvious weight gain or edema, or jaundice or hepatic
damage. Adverse events were elicited by interview at each visit.
All adverse events were reported by each investigator as to duration, severity, and outcome.

Results
Patient population
A total of 131 patients were screened for entry into the study.
Ofthe 113 who qualified for active therapy, 55 were randomly
allocated to receive enteric-coated fenoprofen and 58 to receive
fenoprofen calcium. Another patient, who qualified for active
therapy and participated in the study, was excluded because his
data were unavailable at the time of analysis. Distribution ofthe
113 patients among the six investigators and two treatment
groups was relatively well balanced. The differences between
the two treatment groups were not statistically significant for any
of the variables described below.
Thirty-nine (71%) of the patients receiving enteric-coated
fenoprofen and 45 (78%) receiving fenoprofen calcium were
women. Forty-one (75%) patients receiving enteric-coated
fenoprofen and 45 (78%) receiving fenoprofen calcium were
white; 14 (25%) patients receiving enteric-coated fenoprofen
and 13 (22%) receiving fenoprofen calcium were black. The
knee was the involved osteoarthritic joint in 43 patients receiving enteric-coated fenoprofen and in 50 receiving fenoprofen
calcium. The hip was involved in 12 patients receiving entericcoated fenoprofen and in eight receiving fenoprofen calcium.
Age distribution of patients in the two treatment groups is
given in Table 1. The mean age was 64 years in both groups. In
the group receiving enteric-coated fenoprofen, 48 (87%) of 55
were between 51 and 80 years old. In the group receiving
fenoprofen calcium, 50 (86%) of 58 were in this age range.
On admission to the study, 38 (69%) patients in the entericcoated fenoprofen group and 45 (78%) in the fenoprofen calcium group listed a current sign, symptom, or illness other than
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Table 1
Age Distribution of Patients with Large-Joint
Osteoarthritis Receiving Enteric-Coated Fenoprofen
or Standard Fenoprofen Calcium

Age
< 30
31-40
41-50
51-60
61-70
71-80
> 81

Enteric-Coated
Fenoprofen (n = 55)
Number (%)
of Patients
0
1
4
16
16
16
2

(2)
(7)
(29)
(29)
(29)
(4)

Standard
Fenoprofen Calcium (n = 58)
Number (%)
of Patients
1 (2)
0
5 (9)
13 (22)
23 (40)
14 (24)
2 (3)

osteoarthritis. Forty-one (75%) patients in the enteric-coated
fenoprofen group and 45 (78%) in the fenoprofen calcium group
reported concomitant drug therapy on admission, which continued throughout the study.
During the placebo qualification period, the number of
acetaminophen capsules taken as an analgesic was monitored
and then recorded at the start of the treatment phase. The mean
number of capsules taken was 31 for patients receiving enteric-coated fenoprofen and 30 for patients receiving fenoprofen calcium.
Analysis of efficacy variables
For all efficacy variables, the tests for changes within each
individual treatment group were statistically significant (P <
0.001) for both the endpoint analysis (Table 2) and the monthly
analysis. Thus, patients in both treatment groups experienced
improvement in their disease condition.
The primary analysis of efficacy was the endpoint analysis on
all data (Table 2). No statistically significant differences were
noted between the treatment groups for any of the efficacy measures. Also, the difference at baseline was not significant.
For the secondary analysis of data at each of the three months,
the only statistically significant treatment difference occurred
during the second month for the variables of pain with weightbearing activity and pain on passive motion (Table 3). In both
instances, the group receiving fenoprofen calcium showed

greater improvement than the group receiving enteric-coated
fenoprofen. No statistically significant differences were noted at
the first and third months.
Several visits were considered unevaluable for various reasons such as protocol violation, use of other analgesics, or poor
compliance. Sixteen (29%) patients receiving enteric-coated
fenoprofen and ten (17%) receiving fenoprofen calcium had at
least one visit declared unevaluable; however, this difference
was not statistically significant. When ANOVA was repeated for
the endpoint analysis on evaluable data only, the conclusions did
not differ from those for the analysis of all data. No significant
differences between treatment groups were observed.
The secondary analysis for each of the three months was also
repeated for evaluable data only. Results were similar to those
obtained for the analysis of all data, except that differences for
the two efficacy variables of pain with weight-bearing activity
and pain on passive motion were no longer statistically significant at the second month.
Adverse events
The overall incidence of adverse events was similar for the
two treatment groups, with 36 (65%) of the patients receiving
enteric-coated fenoprofen and 41 (71%) of those receiving standard fenoprofen reporting an adverse event at some time during
the study. Events reported by two or more patients in either treatment group consisted of abdominal pain, flatulence, nausea,
dyspepsia, diarrhea (not otherwise specified), headache, vomiting, constipation, upper respiratory infection, urinary tract infection (not otherwise specified), nasal congestion, sinusttis,
cough, dry mouth, peripheral edema, and potassium deficiency.
No statistically significant differences were noted between treatment groups for any of the adverse events reported during
the study.
Ofthe 13 (11.4%) patients who withdrew from the study because of an adverse experience, five had been receiving entericcoated fenoprofen and eight had been receiving fenoprofen calcium (Table 4). Two patients were withdrawn from the study
when they were hospitalized: one had a myocardial infarction,
and the other had mild vaginal bleeding resulting from a severe
urinary tract infection. One other patient, who was also hospitalized during the study for a urinary tract infection, retumed to

Table 2
Endpoint Analysis of All Data for Four Efficacy Variables on 113 Patients Receiving Enteric-Coated
Fenoprofen or Standard Fenoprofen for TVeatment of Large-Joint Osteoarthritis
Variable
Tenderness on
pressure
Pain at rest
Pain with
weight-bearing
activity
Pain on passive
motion

Endpoint*
0.69 ± 0.77
0.67 ± 0.76

Difference*t
1.31 ± 0.90
1.41 ± 0.80

55
58
55
58

Baseline*
2.00 ± 0.84
2.09 ± 0.76
1.51 ± 0.94
1.64 ± 0.93
2.38 ± 0.71
2.57 ± 0.60

0.62
0.47
1.45
1.40

0.89
1.17
0.93
1.17

55
58

2.00 ± 0.88
2.22 ± 0.73

0.76 ± 0.79
0.79 ± 0.79

Treatment
Enteric-coated
Standard
Enteric-coated
Standard
Enteric-coated
Standard

Number
55
58

Enteric-coated
Standard

±
±
±
±

0.87
0.82
0.81
0.84

±
±
±
±

1.08
1.08
0.90
0.80

1.24 ± 0.92
1.43 ± 0.82

*Mcan ± standard deviation.
r .
tWhen the two treatment groups were compared, the P-valuc of the differences between baseline and endpoint was not signilicant for any of the four
variables. However, within cach treatment group the difference between baseline and endpoint was significanl (P < 0,(X)1) for all four variables.
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Table 3
Second-Month Analysis of All Data for Four Efficacy Variables on Patients Receiving EntericCoated Fenoprofen or Standard Fenoprofen for TVeatment of Large-Joint Osteoarthritis
Variable

Treatment

Number

Baseline*

Endpoint*

Difference*

P-value

Tenderness on
pressure

Enteric-coated
Standard

4,S
52

2,00 ± 0,85
2,08 ± 0,76

0,71 ± 0,58
0,63 ± 0,69

1,29 ± 0,68
1,44 ± 0,80

0,322

Pain at rest

Enteric-coated
Standard

48
52

1,50 ± 0,92
1,56 ± 0,94

0,67 ± 0,75
0,46 ± 0,70

0,83 ± 0,95
1,10 ± 0,98

0.229

Pain with
weight-bearing
activity

Enteric-coated
Standard

4S
52

2,38 ± 0,70
2,52 ± 0,61

1,40 ± 0,71
1,25 ± 0,71

0,98 ± 0,86
1,27 ± 0,79

0.040

Pain on passive
motion

Enteric-coated
Standard

48
52

1,98 ± 0,91
2,19 ± 0,74

0,88 ± 0,70
0,73 ± 0,66

1,10 ± 0,86
1,46 ± 0,80

0.046

*Mean ± standard deviation.

active study medication after she had recovered and completed
the full course of study. No deaths occurred during the study.
Laboratory results
No adverse events were detected by blood chemistty (including liver and renal function) or hematological tests during the
study. No patients withdrew because of hematological events,
and no adverse events were associated with WBC counts in
any patient.
Fifty-three (96%) of the patients receiving enteric-coated
fenoprofen and 54 (93%) receiving standard fenoprofen had
adequate serum samples for determination of drug concentrations. The mean serum concentrations ( ± standard deviation) in
the enteric-coated fenoprofen and standard fenoprofen calcium
groups were 29.5 ± 15.6 pg/mL and 35.6 ± 19.9 pg/mL,
respectively (P = 0.086). However, capsule counts during
the study indicated slightly better compliance in patients receiving standard fenoprofen calcium; mean tablets per day were
3.4 in the group receiving enteric-coated fenoprofen and 3.7
in the group receiving standard fenoprofen (P = 0.028),
which may largely explain the observed differences in mean
semm concentrations.
Withdrawal from the study
Patients were withdrawn from the study for the following reasons; adverse event (13 patients), lack of efficacy (six patients),
patient's decision (one patient), protocol violation (one patient),
and lost to follow-up (one patient). The number of patients
who completed the study included 44 (80%) from the entericcoated fenoprofen group and 47 (81%) from the fenoprofen calcium group.

Discussion
This study was designed to determine whether an entericcoated form of fenoprofen is as effective and safe as standard
fenoprofen. By all four measures of efficacy tested, there were
no consistent statistically significant differences between the
two treatment groups. With both treatments, efficacy measures
improved from baseline to each subsequent visit. Patients who
received enteric-coated fenoprofen experienced the same im-
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Table 4
Adverse Events Resulting in Withdrawal from the Study
in 13 Patients Receiving Enteric-Coated Fenoprofen
or Standard Fenoprofen Calcium for Treatment
of Large-Joint Osteoarthritis
Patient
Number

Adverse Event
Enteric-Coated

1
2
3
4
5

Fenoprofen

Nausea
Moderate epigastric pain
Moderate epigastric pain, nausea
Moderate diarrhea
Blurred vision
Standard Fenoprofen

1
2
3
4
5
6
7
8

Days on Study Drug
Before Treatment
Was Discontinued
56
27
10
29
52

Calcium

Moderate nausea, vomiting.
severe headache
Moderate dyspepsia
Allergic reaction/facial edema
Mild myocardial infarction
Severe urinary tract infection
M i l d diarrhea
Moderate diarrhea
Cardiovascular accident

1
56
98
65
49
74
54
24

provement as those who received standard fenoprofen calcium.
This improvement was the same for both the primary analysis,
which compared baseline and endpoint variables, and for the
secondary analysis, which compared variables at each of the
three months of the treatment phase.
The only statistically significant differences occurred during
the second month of the secondary analysis when all data were
evaluated. At month 2, patients receiving fenoprofen calcium
showed statistically significant greater improvement than patients receiving enteric-coated fenoprofen in the efficacy measures of pain with weight-bearing activity and pain on passive
motion. However, this treatment difference was not significant at
months 1 or 3. Furthermore, when the same analysis was performed on evaluable data only, no statistically significant difference was evident at any of the three months.
The adverse events encountered in this study did not have a
statistically significant difference between the two treatment
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groups and were of a type, severity, and incidence normally seen
with fenoprofen and other NSAIDs (13). No deaths occurred
during the study, and no permanently disabling adverse experiences were attributable to treatment with either formulation of
fenoprofen. Only 13 (11.4%) patients withdrew from the study
because of adverse events, and these patients were evenly distributed between the two treatment groups (eight in the standard
fenoprofen group versus five in the enteric-coated group). Furthermore, most adverse events were minor and mild to moderately severe.
The number of patients completing the study was similar for
the two treatment groups (80% in the enteric-coated fenoprofen
group and 81% in the standard fenoprofen calcium group) and
not unexpected for a three-month clinical study in outpatients.
This double-blind, randomized, parallel study provides evidence that enteric-coated fenoprofen is as effective as standard
fenoprofen calcium for the treatment of large-joint osteoarthritis
with a similar safety profile. Since enteric-coated fenoprofen
reduces the risk of Gl microbleeding (12), it may offer an
additional safety factor for patients who require long-term
administration of NSAIDs for large-joint osteoarthritis.
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